Press releases

Month Year

Email alerts

Oct 28, 2011

Medtronic Receives IDE Approval to Conduct ASPIRE In-Home Study of First Insulin Pump with Low Glucose Suspend for US Market

A Critical Step Toward the Development of an Artificial Pancreas, Low Glucose Suspend Aims to Reduce Hypoglycemia

MINNEAPOLIS, Oct 28, 2011 (BUSINESS WIRE) -- In our continued commitment to develop an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA)...
Oct 27, 2011

FDA Advisory Panel Makes Recommendation on Investigational Medtronic Phased RF Ablation System for Treatment of Persistent or Long-Standing Persistent Atrial Fibrillation

MINNEAPOLIS, Oct 27, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration's (FDA) Circulatory Systems Devices advisory panel voted against...
Oct 26, 2011

Medtronic Starts Landmark Study of Hypertension Treatment

U.S. Clinical Trial of Symplicity(R) Renal Denervation System(TM) Enrolls First Patient

MINNEAPOLIS, Oct 26, 2011 (BUSINESS WIRE) -- Medtronic Inc. (NYSE: MDT) announced today the start of SYMPLICITY HTN-3, the company's U.S. clinical trial of the Symplicity(R) Renal Denervation...
Oct 17, 2011

Medtronic Announces 510(k) Clearance for theAquamantys(R)3 System with Combined Hemostatic Sealing and Cutting Functionality

MINNEAPOLIS, Oct 17, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for its Aquamantys(R)3...
Oct 17, 2011

Medtronic Elects Michael O. Leavitt to the Board of Directors

MINNEAPOLIS, Oct 17, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced that its Board of Directors unanimously voted to elect Michael O. Leavitt, founder and chairman of Leavitt...

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa